BACKGROUND: Diadenosine 5',5'''-P(1),P(4)-tetraphosphate (Ap(4)A), a natural compound stored in platelet dense granules, inhibits ADP-induced platelet aggregation. Ap(4)A inhibits the platelet ADP receptors P2Y(1) and P2Y(12), is a partial agonist of P2Y(12), and is a full agonist of the platelet ATP-gated ion channel P2X1. Modification of the Ap(4)A tetraphosphate backbone enhances inhibition of ADP-induced platelet aggregation. However, the effects of these Ap(4)A analogs on human platelet P2Y(1), P2Y(12) and P2X1 are unclear. OBJECTIVE: To determine the agonist and antagonist activities of diadenosine tetraphosphate analogs towards P2Y(1), P2Y(12), and P2X1. METHODS: We synthesized the following Ap(4)A analogs: P(1),P(4)-dithiotetraphosphate; P(2),P(3)-chloromethylenetetraphosphate; P(1)-thio-P(2),P(3)-chloromethylenetetraphosphate; and P(1),P(4)-dithio-P(2),P(3)-chloromethylenetetraphosphate. We then measured the effects of these analogs on: (i) ADP-induced platelet aggregation; (ii) P2Y(1)-mediated changes in cytosolic Ca(2+); (iii) P2Y(12)-mediated changes in vasodilator-stimulated phosphoprotein phosphorylation; and (iv) P2X1-mediated entry of extracellular Ca(2+). RESULTS: Ap(4)A analogs with modifications in the phosphate backbone inhibited both P2Y(1) and P2Y(12), and showed no agonist activity towards these receptors. The dithio modification increased inhibition of P2Y(1), P2Y(12), and platelet aggregation, whereas the chloromethylene modification increased inhibition of P2Y(12) and platelet aggregation, but decreased P2Y(1) inhibition. Combining the dithio and chloromethylene modifications increased P2Y(1) and P2Y(12) inhibition. As compared with Ap(4)A, each modification decreased agonist activity towards P2X1, and the dual modification completely eliminated P2X1 agonist activity. CONCLUSIONS: As compared with Ap(4)A, tetraphosphate backbone analogs of Ap(4)A have diminished activity towards P2X1 but inhibit both P2Y(1) and P2Y(12) and, with greater potency, inhibit ADP-induced platelet aggregation. Thus, diadenosine tetraphosphate analogs with dual receptor selectivity may have potential as antiplatelet drugs.
BACKGROUND:Diadenosine 5',5'''-P(1),P(4)-tetraphosphate (Ap(4)A), a natural compound stored in platelet dense granules, inhibits ADP-induced platelet aggregation. Ap(4)A inhibits the platelet ADP receptors P2Y(1) and P2Y(12), is a partial agonist of P2Y(12), and is a full agonist of the platelet ATP-gated ion channel P2X1. Modification of the Ap(4)A tetraphosphate backbone enhances inhibition of ADP-induced platelet aggregation. However, the effects of these Ap(4)A analogs on human platelet P2Y(1), P2Y(12) and P2X1 are unclear. OBJECTIVE: To determine the agonist and antagonist activities of diadenosine tetraphosphate analogs towards P2Y(1), P2Y(12), and P2X1. METHODS: We synthesized the following Ap(4)A analogs: P(1),P(4)-dithiotetraphosphate; P(2),P(3)-chloromethylenetetraphosphate; P(1)-thio-P(2),P(3)-chloromethylenetetraphosphate; and P(1),P(4)-dithio-P(2),P(3)-chloromethylenetetraphosphate. We then measured the effects of these analogs on: (i) ADP-induced platelet aggregation; (ii) P2Y(1)-mediated changes in cytosolic Ca(2+); (iii) P2Y(12)-mediated changes in vasodilator-stimulated phosphoprotein phosphorylation; and (iv) P2X1-mediated entry of extracellular Ca(2+). RESULTS:Ap(4)A analogs with modifications in the phosphate backbone inhibited both P2Y(1) and P2Y(12), and showed no agonist activity towards these receptors. The dithio modification increased inhibition of P2Y(1), P2Y(12), and platelet aggregation, whereas the chloromethylene modification increased inhibition of P2Y(12) and platelet aggregation, but decreased P2Y(1) inhibition. Combining the dithio and chloromethylene modifications increased P2Y(1) and P2Y(12) inhibition. As compared with Ap(4)A, each modification decreased agonist activity towards P2X1, and the dual modification completely eliminated P2X1 agonist activity. CONCLUSIONS: As compared with Ap(4)A, tetraphosphate backbone analogs of Ap(4)A have diminished activity towards P2X1 but inhibit both P2Y(1) and P2Y(12) and, with greater potency, inhibit ADP-induced platelet aggregation. Thus, diadenosine tetraphosphate analogs with dual receptor selectivity may have potential as antiplatelet drugs.
Authors: Esmerilda G Delicado; M Teresa Miras-Portugal; Luz María G Carrasquero; David León; Raquel Pérez-Sen; Javier Gualix Journal: Pflugers Arch Date: 2006-05-11 Impact factor: 3.657
Authors: J Pintor; M Díaz-Hernández; J Gualix; R Gómez-Villafuertes; F Hernando; M T Miras-Portugal Journal: Pharmacol Ther Date: 2000 Aug-Sep Impact factor: 12.310
Authors: Pierre Raboisson; Anthony Baurand; Jean-Pierre Cazenave; Christian Gachet; Myriam Retat; Bernard Spiess; Jean-Jacques Bourguignon Journal: J Med Chem Date: 2002-02-14 Impact factor: 7.446
Authors: Hak Sung Kim; Michihiro Ohno; Bin Xu; Hea Ok Kim; Yongseok Choi; Xiao D Ji; Savitri Maddileti; Victor E Marquez; T Kendall Harden; Kenneth A Jacobson Journal: J Med Chem Date: 2003-11-06 Impact factor: 7.446
Authors: Bin Xu; Andrew Stephens; Gary Kirschenheuter; Arthur F Greslin; Xiaoquin Cheng; Joe Sennelo; Marco Cattaneo; Maddalena L Zighetti; Aishe Chen; Soon-Ai Kim; Hak Sung Kim; Norbert Bischofberger; Gary Cook; Kenneth A Jacobson Journal: J Med Chem Date: 2002-12-19 Impact factor: 8.039
Authors: Thomas Gremmel; Ivan B Yanachkov; Milka I Yanachkova; George E Wright; Joseph Wider; Vishnu V R Undyala; Alan D Michelson; Andrew L Frelinger; Karin Przyklenk Journal: Arterioscler Thromb Vasc Biol Date: 2016-01-07 Impact factor: 8.311
Authors: Ivan B Yanachkov; Hung Chang; Milka I Yanachkova; Edward J Dix; Michelle A Berny-Lang; Thomas Gremmel; Alan D Michelson; George E Wright; Andrew L Frelinger Journal: Eur J Med Chem Date: 2015-11-09 Impact factor: 6.514
Authors: Hung Chang; Ivan B Yanachkov; Edward J Dix; Milka Yanachkova; Youfu Li; Marc R Barnard; George E Wright; Alan D Michelson; Andrew L Frelinger Journal: PLoS One Date: 2014-04-10 Impact factor: 3.240